Advances in sphingolipidoses: CRISPR-Cas9 editing as an option for modelling and therapy

Amaral, Olga; Santos, Renato

http://hdl.handle.net/10400.18/6467

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
ijms-20-05897(1).pdf		1.13 MB	Adobe PDF	Download

Send Feedback

Authors

Amaral, Olga

Santos, Renato

Abstract(s)

Sphingolipidoses are inherited genetic diseases characterized by the accumulation of glycosphingolipids. Sphingolipidoses (SP), which usually involve the loss of sphingolipid hydrolase function, are of lysosomal origin, and represent an important group of rare diseases among lysosomal storage disorders. Initial treatments consisted of enzyme replacement therapy, but, in recent decades, various therapeutic approaches have been developed. However, these commonly used treatments for SP fail to be fully effective and do not penetrate the blood-brain barrier. New approaches, such as genome editing, have great potential for both the treatment and study of sphingolipidoses. Here, we review the most recent advances in the treatment and modelling of SP through the application of CRISPR-Cas9 genome editing. CRISPR-Cas9 is currently the most widely used method for genome editing. This technique is versatile; it can be used for altering the regulation of genes involved in sphingolipid degradation and synthesis pathways, interrogating gene function, generating knock out models, or knocking in mutations. CRISPR-Cas9 genome editing is being used as an approach to disease treatment, but more frequently it is utilized to create models of disease. New CRISPR-Cas9-based tools of gene editing with diminished off-targeting effects are evolving and seem to be more promising for the correction of individual mutations. Emerging Prime results and CRISPR-Cas9 difficulties are also discussed.

Description

We acknowledge the collaboration of Meg Quint in the proofreading of the manuscript and the team at the Unit of R&D of DGH at INSA-Porto for the agreeable environment provided.